We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple Blood Test Rapidly Diagnoses Rare Neurometabolic Condition

By LabMedica International staff writers
Posted on 07 Jun 2023
Print article
Image: A new diagnostic blood test can detect a rare but treatable condition called De Vivo disease (Photo courtesy of Freepik)
Image: A new diagnostic blood test can detect a rare but treatable condition called De Vivo disease (Photo courtesy of Freepik)

De Vivo disease, also known as glucose transporter type 1 deficiency syndrome (GLUT1-DS), is an uncommon but manageable condition usually characterized by developmental delays, epilepsy, and/or movement disorders in children. Despite the availability of metabolic therapies that can significantly improve symptoms, including epileptic seizures, prompt diagnosis is vital as these treatments are most beneficial when initiated early. Unfortunately, current diagnostic measures often involve invasive methods such as lumbar punctures or complex DNA analysis, which limits their usage. Now, a simple and rapid blood test that is capable of diagnosing De Vivo disease with ease in both adults and children within 48 hours offers a breakthrough for detecting this rare but treatable condition.

A group of researchers from the AP-HP Paris (Paris, France) public hospitals network has developed an innovative diagnostic blood test for De Vivo disease that enables rapid screening for the condition. The revolutionary test has the potential to streamline screening for all patients presenting symptoms such as cognitive impairment, movement disorders, epilepsy, or a combination of these conditions.

In a trial involving 30 De Vivo disease patients of varying ages and symptoms, the diagnostic blood test was compared with samples from 346 healthy individuals. The test demonstrated significant reliability, accurately identifying 78% of De Vivo disease patients, including those with inconclusive genetic analysis. Encouraged by these findings, the researchers have recommended incorporating the new test in standard clinical practice across all neuropediatric and neurology departments. Given its simplicity, the team is optimistic that the test will allow for the diagnosis of more patients with De Vivo disease.

Related Links:
AP-HP Paris 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more